US 12,391,764 B2
Anti-CD30 and anti-CD3 bispecific antibodies and methods of immunotherapy for CD30+ malignancies
Jeffrey A. Medin, Shorewood, WI (US); Lawrence G. Lum, Charlottesville, VA (US); Robyn A. A. Oldham, Milwaukee, WI (US); and Archana Thakur, Charlottesville, VA (US)
Assigned to The Medical College of Wisconsin, Inc., Milwaukee, WI (US); and University of Virginia Patent Foundation, Charlottesville, VA (US)
Filed by Medical College of Wisconsin, Inc., Milwaukee, WI (US); and University of Virginia Patent Foundation, Charlottesville, VA (US)
Filed on Apr. 17, 2023, as Appl. No. 18/301,924.
Application 18/301,924 is a continuation of application No. 16/580,625, filed on Sep. 24, 2019, granted, now 11,667,721.
Claims priority of provisional application 62/735,576, filed on Sep. 24, 2018.
Prior Publication US 2023/0312738 A1, Oct. 5, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01)
CPC C07K 16/2878 (2013.01) [A61K 39/39583 (2013.01); A61P 35/00 (2018.01); C07K 16/2809 (2013.01); A61K 39/3955 (2013.01); C07K 14/7051 (2013.01); C07K 14/70578 (2013.01); C07K 16/283 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01)] 34 Claims
 
1. An isolated bispecific antibody capable of binding human CD30 and to CD3 comprising an anti-CD30 antibody or antigen binding portion thereof and an anti-CD3 antibody or antigen binding portion thereof, wherein the anti-CD30 antibody or antigen binding portion thereof comprises:
(a) a light chain variable domain comprising a CDRL1 region of SEQ ID NO:_2 or a sequence with at least 90% similarity to SEQ ID NO:_2, a CDRL2 region of SEQ ID NO:_3 or a sequence with at least 90% similarity to SEQ ID NO:_3, and a CDRL3 region of SEQ ID NO:_4 or a sequence with at least 90% similarity to SEQ ID NO:_4 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO:_6 or a sequence with at least 90% similarity to SEQ ID NO:_6, a CDRH2 region of SEQ ID NO:_7 or a sequence with at least 90% similarity to SEQ ID NO:_7, and a CDRH3 region of SEQ ID NO:_8 or a sequence with at least 90% similarity to SEQ ID NO:_8;
(b) a light chain variable domain comprising a CDRL1 region of SEQ ID NO: 10 or a sequence with at least 90% similarity to SEQ ID NO: 10, a CDRL2 region of SEQ ID NO: 11 or a sequence with at least 90% similarity to SEQ ID NO: 11, and a CDRL3 region of SEQ ID NO:_12 or a sequence with at least 90% similarity to SEQ ID NO: 12 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO: 14 or a sequence with at least 90% similarity to SEQ ID NO:_14, a CDRH2 region of SEQ ID NO:_15 or a sequence with at least 90% similarity to SEQ ID NO:_15, and a CDRH3 region of GAY or a sequence with at least 90% similarity to GAY;
(c) a light chain variable domain comprising a CDRL1 region of SEQ ID NO:_18 or a sequence with at least 90% similarity to SEQ ID NO: 18, a CDRL2 region of SEQ ID NO: 19 or a sequence with at least 90% similarity to SEQ ID NO: 19, and a CDRL3 region of SEQ ID NO:_20 or a sequence with at least 90% similarity to SEQ ID NO:_20 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO:_22 or a sequence with at least 90% similarity to SEQ ID NO:_22, a CDRH2 region of SEQ ID NO:_23 or a sequence with at least 90% similarity to SEQ ID NO: 23, and a CDRH3 region of SEQ ID NO:_24 or a sequence with at least 90% similarity to SEQ ID NO:_24;
(d) a light chain variable domain comprising a CDRL1 region of SEQ ID NO:_26 or a sequence with at least 90% similarity to SEQ ID NO: 26, a CDRL2 region of SEQ ID NO:_27 or a sequence with at least 90% similarity to SEQ ID NO:_27, and a CDRL3 region of SEQ ID NO:_28 or a sequence with at least 90% similarity to SEQ ID NO:_28 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO:_30 or a sequence with at least 90% similarity to SEQ ID NO:_30, a CDRH2 region of SEQ ID NO:_31 or a sequence with at least 90% similarity to SEQ ID NO:_31, and a CDRH3 region of SEQ ID NO:_32 or a sequence with at least 90% similarity to SEQ ID NO:_32; or
(e) a light chain variable domain comprising a CDRL1 region of SEQ ID NO:_34 or a sequence with at least 90% similarity to SEQ ID NO:_34, a CDRL2 region of SEQ ID NO:_35 or a sequence with at least 90% similarity to SEQ ID NO:_35, and a CDRL3 region of SEQ ID NO:_36 or a sequence with at least 90% similarity to SEQ ID NO:_36 and a heavy chain variable domain comprising a CDRH1 region of SEQ ID NO:_38 or a sequence with at least 90% similarity to SEQ ID NO:_38, a CDRH2 region of SEQ ID NO:_39 or a sequence with at least 90% similarity to SEQ ID NO:_39, and a CDRH3 region of SEQ ID NO:_40 or a sequence with at least 90% similarity to SEQ ID NO:_40.